科研成果详情

题名A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors
作者
发表日期2023-05-10
发表期刊SIGNAL TRANSDUCTION AND TARGETED THERAPY   影响因子和分区
语种英语
原始文献类型Article
其他关键词HOMOLOGOUS RECOMBINATION-DEFICIENT ; OLAPARIB MAINTENANCE THERAPY ; PARP INHIBITOR OLAPARIB ; OVARIAN-CANCER ; PHASE-II ; REPAIR ; CELLS ; BIOGENESIS ; ATM ; SENSITIVITY
摘要Poly (ADP-ribose) polymerase (PARP) inhibitors are one of the most exciting classes of targeted therapy agents for cancers with homologous recombination (HR) deficiency. However, many patients without apparent HR defects also respond well to PARP inhibitors/cisplatin. The biomarker responsible for this mechanism remains unclear. Here, we identified a set of ribosomal genes that predict response to PARP inhibitors/cisplatin in HR-proficient patients. PARP inhibitor/cisplatin selectively eliminates cells with high expression of the eight genes in the identified panel via DNA damage (ATM) signaling-induced pro-apoptotic ribosomal stress, which along with ATM signaling-induced pro-survival HR repair constitutes a new model to balance the cell fate in response to DNA damage. Therefore, the combined examination of the gene panel along with HR status would allow for more precise predictions of clinical response to PARP inhibitor/cisplatin. The gene panel as an independent biomarker was validated by multiple published clinical datasets, as well as by an ovarian cancer organoids library we established. More importantly, its predictive value was further verified in a cohort of PARP inhibitor-treated ovarian cancer patients with both RNA-seq and WGS data. Furthermore, we identified several marketed drugs capable of upregulating the expression of the genes in the panel without causing HR deficiency in PARP inhibitor/cisplatin-resistant cell lines. These drugs enhance PARP inhibitor/cisplatin sensitivity in both intrinsically resistant organoids and cell lines with acquired resistance. Together, our study identifies a marker gene panel for HR-proficient patients and reveals a broader application of PARP inhibitor/cisplatin in cancer therapy.
资助项目Department of Oncology[PEO1/ABT-888];key research and development program of Zhejiang province[2019C03010];National Natural Science Foundation of China[81772787,82072889];CSCO[Y-2019AZZD-0359];National Key Technology Research and Development Program of China[2022YFC2704200,2022YFC2704205];
出版者SPRINGERNATURE
ISSN2095-9907
EISSN2059-3635
卷号8期号:1
DOI10.1038/s41392-023-01401-y
页数17
WOS类目Biochemistry & Molecular Biology ; Cell Biology
WOS研究方向Biochemistry & Molecular Biology ; Cell Biology
WOS记录号WOS:000992507500001
收录类别SCIE ; PUBMED ; SCOPUS
URL查看原文
Pubmed记录号37160887
Scopus记录号2-s2.0-85158997035
自科自定义期刊分类T3(B)类
通讯作者地址[Lou, Zhenkun]Department of Oncology,Mayo Clinic,Rochester,55905,United States ; [Gao, Qinglei]Cancer Biology Research Center (Key Laboratory of the Ministry of Education),Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei,Wuhan,430030,China ; [Cheng, Xiaodong]Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Reproductive Health Research,Zhejiang,Hangzhou,310006,China ; [Yuan, Jian]Key Laboratory of Arrhythmias of the Ministry of Education of China,Research Center for Translational Medicine,East Hospital,Tongji University School of Medicine,Shanghai,200120,China ; [Zhang, Jin-San]The Quzhou Affiliated Hospital of Wenzhou Medical University,Quzhou People’s Hospital,Zhejiang,Quzhou,324000,China
scopus学科分类Genetics;Cancer Research
引用统计
文献类型期刊论文
条目标识符https://kms.wmu.edu.cn/handle/3ETUA0LF/180009
专题药学院(分析测试中心)
附属第一医院
其他_温州医科大学附属衢州医院
通讯作者Cheng, Xiaodong; Gao, Qinglei; Yuan, Jian; Lou, Zhenkun; Zhang, Jin-San
作者单位
1.Beijing Institute of Basic Medical Sciences,Beijing,100850,China;
2.Department of Oncology,Mayo Clinic,Rochester,55905,United States;
3.School of Pharmaceutical Sciences,Wenzhou Medical University,Zhejiang,Wenzhou,325035,China;
4.Key Laboratory of Endocrine Gland Diseases of Zhejiang Province,Zhejiang Provincial People’s Hospital,Zhejiang,Hangzhou,310014,China;
5.Department of Gynecology,Zhejiang Provincial People’s Hospital,Zhejiang,Hangzhou,310014,China;
6.Department of Gynecology,the First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China;
7.Wuhan Kingwise Biotechnology Co.,Ltd.,Hubei,Wuhan,430206,China;
8.Cancer Biology Research Center (Key Laboratory of the Ministry of Education),Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei,Wuhan,430030,China;
9.Department of Gynecological Oncology,Sun Yat-sen Memorial Hospital,Sun Yat-sen University,Guangdong,Guangzhou,510120,China;
10.Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Reproductive Health Research,Zhejiang,Hangzhou,310006,China;
11.Zhejiang Provincial Key Laboratory of Precision Diagnosis and Therapy for Major Gynecological Diseases,Zhejiang,Hangzhou,310006,China;
12.Department of Molecular Pharmacology and Experimental Therapeutics,Mayo Clinic,Rochester,55905,United States;
13.Department of Dermatology,University of California San Diego,San Diego,92122,United States;
14.Key Laboratory of Saline-alkali Vegetation Ecology Restoration,Ministry of Education,College of Life Science,Northeast Forestry University,Harbin,150040,China;
15.Division of Gynecology Oncology,Department of Obstetrics and Gynecology,Qilu Hospital,Shandong University,Shandong,Jinan,250012,China;
16.Department of Obstetrics and Gynecology,the First Affiliated Hospital,Sun Yat-Sen University,Guangdong,Guangzhou,510080,China;
17.Department of Gynecologic Oncology,Obstetrics and Gynecology Hospital of Fudan University,Shanghai,200090,China;
18.Department of Gynecologic Oncology,National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital,Chinese Academy of Medical Sciences and Peking Union Medical College,Beijing,100021,China;
19.Department of Radiation Oncology,Hubei Cancer Hospital,Tongji Medical College,Huazhong University of Science and Technology,Hubei,Wuhan,430030,China;
20.Department of Gynecologic Oncology,Women’s Hospital,School of Medicine,Zhejiang University,Zhejiang,Hangzhou,310006,China;
21.Key Laboratory of Arrhythmias of the Ministry of Education of China,Research Center for Translational Medicine,East Hospital,Tongji University School of Medicine,Shanghai,200120,China;
22.Department of Biochemistry and Molecular Biology,Tongji University School of Medicine,Shanghai,200120,China;
23.The Quzhou Affiliated Hospital of Wenzhou Medical University,Quzhou People’s Hospital,Zhejiang,Quzhou,324000,China;
24.Medical Research Center,and Key Laboratory of Interventional Pulmonology of Zhejiang Province,The First Affiliated Hospital of Wenzhou Medical University,Zhejiang,Wenzhou,325000,China
通讯作者单位温州医科大学附属衢州医院
推荐引用方式
GB/T 7714
Zhang, Chao,Guo, Qiang,Chen, Lifeng,et al. A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors[J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY,2023,8(1).
APA Zhang, Chao., Guo, Qiang., Chen, Lifeng., Wu, Zheming., Yan, Xiao-Jian., ... & Zhang, Jin-San. (2023). A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 8(1).
MLA Zhang, Chao,et al."A ribosomal gene panel predicting a novel synthetic lethality in non-BRCAness tumors".SIGNAL TRANSDUCTION AND TARGETED THERAPY 8.1(2023).

条目包含的文件

条目无相关文件。
个性服务
查看访问统计
谷歌学术
谷歌学术中相似的文章
[Zhang, Chao]的文章
[Guo, Qiang]的文章
[Chen, Lifeng]的文章
百度学术
百度学术中相似的文章
[Zhang, Chao]的文章
[Guo, Qiang]的文章
[Chen, Lifeng]的文章
必应学术
必应学术中相似的文章
[Zhang, Chao]的文章
[Guo, Qiang]的文章
[Chen, Lifeng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。